Navigation Links
Zafgen Secures $45 Million in Series E Financing
Date:12/4/2013

CAMBRIDGE, Mass., Dec. 4, 2013 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $45 million in a Series E equity financing.  New investors include RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor, and a private investor.  Proceeds from the financing will be used to support the continued development of beloranib, the Company's obesity therapeutic.  Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.

"We are excited to add this group of new investors to our syndicate and to obtain continued investment from Alta Partners who led our Series D round last year, as we continue to advance our clinical testing for beloranib in severe obesity and related orphan indications," said Thomas Hughes, Ph.D., president and chief executive officer, Zafgen, Inc.  "With their support, we look forward to building on our recent Phase 2 results and expanding the beloranib program to help patients who suffer from these serious diseases."  

"Zafgen has continued to attract high quality investors to its syndicate in support of beloranib," said Peter Barrett of Atlas Venture and Chairman of the Board of Zafgen.  "Zafgen's newest investors support some of the most innovative companies and their investment demonstrates confidence in beloranib as a unique pharmacotherapeutic with the potential to address the unmet needs of severely obese patients."

About Zafgen, Inc.

Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients and related orphan indications by bringing beloranib, a first-in-class no
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
4. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
5. Calithera Biosciences Secures $35 Million in Series D Financing
6. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
7. Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
8. Predilytics Secures Additional Funding and Expands Board of Directors
9. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
10. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
11. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
... 16, 2012 /PRNewswire-iReach/ -- Chronic pain is ... causes of persistent, debilitating back pain. Chicago resident Pedro ... livelihood and soured his outlook on life. After taking ... he finally found relief with non-surgical treatment at the ...
...  Rubicon Genomics, Inc., a leader in the development ... the performance and capabilities of DNA and RNA ... announced the launch of the first product in ... designed and optimized for next generation sequencing (NGS).  ...
Cached Medicine Technology:The Illinois Back Institute Helps Patient Beat Debilitating Back Pain 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 3
(Date:7/23/2014)... (PRWEB) July 23, 2014 “Unlike most ... focus on developing your own unique gifts, talents and ... and clichéd sales verbiage, “says Ja Marr Brown. ... Sales Story?" which chronicles Brown’s transformation from nearly getting ... of The Year, winning every sales contest offered and ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The ... ratified today a robust trial for a defined ... of risk adjusting relevant quality measures for sociodemographic ... NQF policy.     , Sociodemographic factors can be socioeconomic, ... race, ethnicity, and primary language. Growing evidence ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, ... overweight American children and teens look in the mirror ... officials reported Wednesday. "Being overweight or obese is ... pressure, high cholesterol and diabetes," said lead researcher Neda ... Disease Control and Prevention,s National Center for Health Statistics. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Inventor and ... From football games to the gas pump – sharing ... on Wednesday, July 30 at Noon. , With 24 ... has more patents than anyone in the General Assembly ... superimposed yellow line yard marker as seen on television, ...
Breaking Medicine News(10 mins):Health News:Using Your Story and Not Technique to Achieve Sales Success 2Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
... synthetic bone matrix offers hope for babies born with craniosynostosis, ... fuse too soon. Implants replacing some of the infant,s bone ... currently used to treat the condition. "The remarkable thing ... matrix changes what the cells around it do. Cells begin ...
... disease, stroke more likely for organ recipients with sleep ... News) -- Kidney transplant patients with sleep apnea are ... and stroke, Hungarian researchers say. , The study of ... moderate to severe sleep apnea, a rate similar to ...
... and costs, study finds , THURSDAY, Nov. 19 (HealthDay ... angiography is quicker, more accurate and much less expensive ... to moderate enzyme and EKG scores, according to a ... pain patients at 16 emergency rooms who were randomly ...
... 19 2009 has been a monumental year for ... from QUITPLAN Services, QuitCash Challenge, helped the 31-year-old Columbia ... The Challenge. Nearly 2,000 Minnesotans, including Doug, attempted to ... win the $5,000 grand prize. , On Thursday, November ...
... Official Statement by Teamsters General President Jim Hoffa ... Jim Hoffa issued the following statement today about the Senate ... health plans that will mean a huge middle-class tax hike ... would impose an excise tax on insurers for higher-cost health ...
... Nov. 19 Monogram Energy, Inc. ("Monogram") (Pink Sheets: ... of Triad Therapeutics, Inc. ("Triad"), which was effective as ... the Stock Purchase and Recapitalization Agreement, shareholders of Monogram ... exchange for approximately 95% ownership to the Triad shareholders ...
Cached Medicine News:Health News:Bone implant offers hope for skull deformities 2Health News:Kidney Transplant, Sleep Disorder May Add Up to Trouble 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 3Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: